Get 50% OFF This Summer!

Advertisement
logo

Medicamen Biotech

MEDICAMEQ
Micro Cap
(%) 1D
no_data

No Data Available

1D1W1M3M6M1YMAX

Investor Sentiment

50%50%
Bullish
Bearish
Advertisement

Medicamen Biotech Share price and Fundamental Analysis

View All Details
View All Details
Medicamen Biotech Ltd is a widely held, Globally Recognized public limited company engaged in manufacturing and marketing of pharmaceutical formulations in overseas and domestic markets. The company is engaged in manufacture and distribution of medicines. They manufacturer and supply the range of products such as tablets, capsules, liquid syrup and dry syrup (beta lactum and non beta lactum) and ointment.
Company Incorporation1993
ChairmanRahul Bishnoi
Head QuartersNA
Previous NameNA

Key Metrics

Market Cap (Cr)
554.74
PE Ratio
66.01
Industry P/E
35.21
PEG Ratio
-2.19
ROE
3.4%
ROCE
5.81%
ROA
2.31%
Total Debt (Cr)
20.17
Debt to Equity
0.09
Dividend Yield
0.23%
EPS
6.61
Book Value & P/B
169.82 x 2.57
Face Value
10
Outstanding Shares(Cr)
1.27
Current Ratio
3.13
EV to Sales
3.15

Stock Returns

1 Week+2.13%
1 Month-11.41%
6 Months-4.5%
1 Year-11.34%
3 Years-33.61%
5 Years-20.58%

CAGR

1 Year CAGR

Revenue Growth

0%

Net Profit Growth

0%

Operating Profit Growth

0%

Dividend Growth

0%

Stock Returns CAGR

-11.34%
no_data

No Stocks

Smart Score

1.9
icn

Unlock Smart Score

See Detailed Analysis & Insights

icn

Unlock Insights

See Detailed Analysis & Insights

Technicals

Returns Calculator

If you would have invested
In 5 years the current value would be
NaNCRNaNCR( %)

Research Report

No Research Report

View Other Reports >

Corporate Action

Board-Meetings
Board-Meetings
Dividends
Bonus
Splits
Right-issues
AGM-EGM
Bulk-Deal
Block-Deal

Financials

Half Yearly Statement

/ View Standalone

Profit and Loss Statement

/ View Standalone
Credit Rating
Director Report
Chairman Report
Auditor Report

Balance sheet

/ View Standalone

Cashflow Statement

/ View Standalone
Apr 25

Promoters : 40.46%

FIIs : 0.22%

DIIs : 0.65%

Public : 58.67%

Promoter
FII/FPI
DII
Public
Promoter Pledge stands at 0.0% of holding in April 2025 Qtr
FII Shareholding Increased by 0.11% to 0.22% in April 2025 Qtr
Promoter Shareholding Decreased by 2.7% to 40.46% in April 2025 Qtr
DII Shareholding Decreased by 0.04% to 0.65% in April 2025 Qtr

Top Shareholders

View all Share Holders

Key Ratios

Profitability
Valuation
Liquidity

ROE

Avg ROE (3 Yrs) : NaN%

ROCE

Avg ROCE (3 Yrs) : NaN%

ROA

Avg ROA (3 Yrs) : NaN%

NPM

Avg NPM (3 Yrs) : NaN%

Dividend History

Medicamen Biotech Competitors

Sector
Industry

Company Name

MCap(TTM)

PE(TTM)

P/B(TTM)

ROE(TTM)

D/E

Current Ratio(TTM)

5 Year FactSheet

Profitability
Profitability
Growth Ratios
Valuation Ratios
Cashflow Ratios
Debt and Liquidity
Efficiency Ratios

Documents

Annual Reports
Con-Call

News

Medicamen Biotech Management and History

Company Management

icn

Unlock Management Data

See Detailed Analysis & Insights

Company History

Medicamen Biotech Ltd is a widely held, Globally Recognized public limited company engaged in manufacturing and marketing of pharmaceutical formulations in overseas and domestic markets. The company is engaged in manufacture and distribution of medicines. They manufacturer and supply the range of products such as tablets, capsules, liquid syrup and dry syrup (beta lactum and non beta lactum) and ointment.

The company has two manufacturing facilities namely, Bhiwadi (Rajasthan) and Haridwar (Uttarakhand). The Bhiwadi unit has ultra modern production facilities incorporating latest state of the art technology with a combination of technically qualified personnel and hardworking workforce. In Haridwar unit, the company manufactures Non-Betalactum preparations including tablets, capsules, oral liquids and ointments & creams.

The company is committed to produce and provide quality medicines at competitive price for domestic as well as international markets thereby being socially responsible and rendering services to the medical Fraternity.

Medicamen Biotech Ltd was incorporated on December 1993 and started their operation as distributor and manufacturer of medicines on loan license basis. The distribution activities were spread manifold over a wide market extending beyond the domestic market and started exporting to CIS countries.

The vast distribution network with demand for low cost medicines prompted the company to go for own manufacturing facilities. Thus, in the year 1994, a land of 210,000 square feet in the Industrial town of Bhiwadi in the state of Rajasthan was procured. In the year 1995, the company was enlisted in Bombay Stock Exchange.

In the year 2005, the company installed the second unit in the tax free zone at Haridwar in Uttarakhand, keeping the space with the ever increase in demand and fulfilling the commitment.

During the year 2006-07, the company added Analgesic and Anti bacterial, Anti filarial and Anti TB products in its range and done two mega projects of Govt. of India related to Anti filarial and Anti TB drugs. They also supplied Anti bacterial products like Cotrimoxazole and Anti Analgesics like Paracetamol in bulk to their foreign partners. During the year, the company increased the production capacity of Tablets by 600 lakh Nos to 7800 lakh Nos.

The second unit in Haridwar became fully operational from April 2007 with ultra modern manufacturing facilities comprises of Non Betalactum Tablets, Capsules, oral liquids & ointments with the production capacity of 4100 lakh Nos, 600 lakh Nos, 6 lakh Litre and 0.30 lakh kg respectively. The company upgraded the Bhiwadi unit with a consolidated cost of more than Rs 2.5 crore under the latest WHO guidelines on CGMP.'

The Company launched the marketing division in Jan'09, with 16 products in Delhi & Uttrakhand regions. On September 16, 2015, M/s. Shivalik Rasayan Limited (Acquirer) got into two Share Purchase Agreements(SPAs) with Promoters of the Company - SPA 1 with Mr. Bal Kishan Gupta, Mr. Ashutosh Gupta, Ms. Ritu Gupta, Ms. Suchita Gupta and SPA 2 with Mr. Abhishek Bansal, Ms. Manju Bansal, Mr. Sanjay Bansal and Ms. Ayushi Bansal for the acquisition of 44,12,095 fully paid-up Equity Shares of Rs.10/- each representing 44.15% of the paid up equity share capital of the Company through which the Acquirer made a Takeover Open Offer Transaction to acquire 26% of the Paid up Capital of the Company, which was completed in December, 2015 and the Acquirer became New Promoter of the Company.

The Company acquired 100% stake of OPAL Pharmaceuticals Pty Ltd from its existing shareholder aggregating upto (AUD) $4,20,000 in 2019-20. OPAL, a wholly owned subsidiary of the Company, merged with the Company effective September 17, 2019. The Company has launched 12 Oncology products in domestic market effective from January, 2022.

Medicamen Biotech Share Price

Medicamen Biotech share price reflects investor sentiment toward the company and is impacted by various factors such as financial performance, market trends, and economic conditions. Share price is an indicator which shows the current value of the company's shares at which buyers or sellers can transact.

Medicamen Biotech Market Cap

Market capitalization of Medicamen Biotech indicates the total value of its outstanding shares. Marketcap is calculated by multiplying share price and outstanding shares of the company. It is a helpful metric for assessing the company's size and market Valuation. It also helps investors understand how Medicamen Biotech is valued compared to its competitors.

Medicamen Biotech PE Ratio

Medicamen Biotech PE ratio helps investors understand what is the market value of each stock compared to Medicamen Biotech 's earnings. A PE ratio higher than the average industry PE could indicate an overvaluation of the stock, whereas a lower PE compared to the average industry PE could indicate an undervaluation.

Medicamen Biotech PEG Ratio

The PEG ratio of Medicamen Biotech evaluates its PE ratio in relation to its growth rate. A PEG ratio of 1 indicates a fair value, a PEG ratio of less than 1 indicates undervaluation, and a PEG ratio of more than 1 indicates overvaluation.

Medicamen Biotech ROE (Return on Equity)

Return on Equity (ROE) measures how effectively Medicamen Biotech generates profit from shareholders' equity. A higher ROE of more than 20% indicates better financial performance in terms of profitability.

Medicamen Biotech ROCE (Return on Capital Employed)

Return on Capital Employed (ROCE) evaluates the profitability of Medicamen Biotech in relation to its capital employed. In simple terms, ROCE provides insight to investors as to how well the company is utilizing the capital deployed. A high ROCE of more than 20% shows that the business is making profitable use of its capital.

Medicamen Biotech Total Debt

Total debt of Medicamen Biotech shows how much the company owes to either banks or individual creditors. In simple terms, this is the amount the company has to repay. Total debt can be a very useful metric to show the financial health of the company. Total debt more than equity is considered to be a bad sign.

Medicamen Biotech Debt to Equity Ratio

The Debt-to-Equity (DE) ratio of Medicamen Biotech compares its total debt to shareholders' equity. A higher Debt to Equity ratio could indicate higher financial risk, while a lower ratio suggests that the company is managing its debt efficiently.

Medicamen Biotech CAGR (Compound Annual Growth Rate)

CAGR shows the consistent growth rate of Medicamen Biotech over a specific period, whether it is over a month, a year, or 10 years. It is a key metric to evaluate the company’s long-term growth potential. Main metrics for which CAGR is calculated are net sales, net profit, operating profit, and stock returns.

Medicamen Biotech Technical Analysis

Technical analysis of Medicamen Biotech helps investors get an insight into when they can enter or exit the stock. Key components of Medicamen Biotech Technical Analysis include:

Support Levels (S1, S2, S3)

There are usually multiple support levels, but the main support levels for a stock are S1, S2, S3. Support levels indicate price points where stock might get support from buyers, helping the stock stop falling and rise.

Resistance Levels (R1, R2, R3)

There are usually multiple resistance levels, but the main resistance levels for a stock are R1, R2, R3. Resistance levels represent price points where Medicamen Biotech shares often struggle to rise above due to selling pressure.

Medicamen Biotech Dividends

Dividends refer to the portion of the company’s profits distributed to its shareholders. Dividends are typically paid out in cash and reflect Medicamen Biotech ’s financial health and profitability.

Medicamen Biotech Bonus Shares

Bonus shares are usually given by companies to make the stock more affordable, increase liquidity, boost investor confidence, and more.

Medicamen Biotech Stock Split

Stock split increases the number of its outstanding shares by dividing each existing share into multiple shares. When the company offers a stock split, the face value of the stock reduces in the same proportion as the split ratio.

Medicamen Biotech Financials

The financials of Medicamen Biotech provide a complete view to investors about its net sales, net profit, operating profits, expenses, and overall financial health. Investors can analyze financial data to assess the company’s stability and also understand how the company has been growing financially.

Medicamen Biotech Profit and Loss Statements

The profit and loss statement of Medicamen Biotech highlights its net sales, net profit, total expenditure, and operating profits in the current financial year. This Profit and Loss statement is crucial for evaluating the profitability and financial stability of Medicamen Biotech .

Medicamen Biotech Balance Sheet

The balance sheet presents a snapshot of Medicamen Biotech ’s assets, liabilities, and equity of shareholders, providing insights into the financials of the company.

Medicamen Biotech Cashflow Statements

Cashflow statements track the company's cash inflows and outflows over a period. It is an essential tool for understanding how well the company manages its liquidity and finances.

Download the App